William Lewis, the CEO of Insmed, has been at the helm since September 2012, bringing a wealth of experience from the biopharmaceutical industry. Before joining Insmed, he co-founded Aegerion Pharmaceuticals, where he served as President and CFO, focusing on treatments...

William Lewis, the CEO of Insmed, has been at the helm since September 2012, bringing a wealth of experience from the biopharmaceutical industry. Before joining Insmed, he co-founded Aegerion Pharmaceuticals, where he served as President and CFO, focusing on treatments for rare diseases. Lewis has a strong background in finance and investment banking, having worked at major firms like J.P. Morgan and Wells Fargo. Under his leadership, Insmed has made significant strides, notably advancing its flagship product ALIS for treating lung disease and achieving impressive corporate goals. In 2017, his compensation was nearly $4.35 million, mainly driven by performance metrics tied to the company's progress in product development. Lewis has been involved in significant insider trading, with notable transactions peaking at around $65.99 million in value as of August 2024, indicating a strong alignment of his interests with those of investors. He has also structured his compensation to match corporate success, reflecting a modern approach to executive pay that emphasizes accountability. He studied the market deeply and has built valuable relationships while ensuring that Insmed is well-positioned in the competitive pharmaceutical landscape.